Ainos (AIMD) Issues Mid-Year Update
FREE Breaking News Alerts from StreetInsider.com!
- Wall St ends mixed as tech megacap declines outweigh upbeat chip outlook
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- IBM surges on unveiling sub-1nm chip technology breakthrough
- 'Long-term deals significant positive for stock:' Analysts react to Micron results
- Needham Starts NeoVolta (NEOV) at Buy
- Two major earthquakes strike Venezuela, killing at least 32 and injuring hundreds
- Hertz cuts guidance, announces notes and stock offerings, shares sink
- Wall St ends mixed as tech megacap declines outweigh upbeat chip outlook
- SanDisk stock target lifted by Citi on continued demand strength
Ainos Issues Mid-Year Update: Reaching Strategic Inflection in SmellTech and Immunotherapy
June 16, 2025 8:01 AM EDTAI Nose Platform Advances Toward Scaled Pilot Programs Across Healthcare, Robotics, and Industrials
VELDONA® Oral Interferon Receives Approval to Begin Human Trials in Taiwan
SAN DIEGO, CA / ACCESS Newswire / June 16, 2025 / Ainos, Inc. (NASDAQ: AIMD)(NASDAQ: AIMDW) ("Ainos" or the "Company") today issued a mid-year update outlining key strategic milestones achieved during the first half of 2025. The Company has transitioned from R&D to commercial execution, marked by its first AI Nose-driven... More
